✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Status◇ research
Dissolved
Status Detail
Out of business with no active operations since approximately 2015, no formal dissolution date confirmed
Exit Type◇ research
Shutdown
Subsequent Funding◇ research
$190,000
Received VC Funding◇ research
—
Current Employees◇ research
—
Peak Employees◇ research
—
SBIR/STTR Awards◇ research
$280,627
Filed Form D◇ research
No
Used Crowdfunding◇ research
No
Notes
KY Angel PDF shows six 2015 qualified investments totaling $190,000 actual investment. UK commercialization news from 2011 reported $500,000 in matching funds to develop a device that removes aluminum contamination from IV fluids. SBIR/STTR records show an earlier federal award. A 2025 PitchBook snippet identifies the company as out of business; next pass should verify the formal dissolution/closure date in state records.
[Deep research 2026-04-11] Research confirmed no USPTO patents filed despite developing ACE filter technology. SBIR/STTR funding totaled $280,627: $213,542 from NIH in 2011 and $67,085 via University of Missouri pass-through award (CFDA 93.865). Robert A. Yokel identified as founder and President. No crowdfunding campaigns or SEC Form D filings found. Company developed hydroxamic acid-based aluminum removal device for calcium gluconate injections but ceased operations around 2015 with no formal exit announcement.
Last updated: Apr 11, 2026 · Evidence score: 4/5